<DOC>
	<DOCNO>NCT01265979</DOCNO>
	<brief_summary>The purpose study evaluate WB DWI early predictor response treatment regorafenib placebo patient advance metastatic GIST .</brief_summary>
	<brief_title>WB-DWI Early Prediction Therapy Response Patients With Advanced Metastatic GIST Treated With Regorafenib</brief_title>
	<detailed_description>Aim study - To assess whole body diffusion-weighted magnetic resonance imaging ( WB-DWI ) assessment early prediction response treatment regorafenib placebo patient advance , metastatic gastro-intestinal stromal tumor ( GIST ) 1 . Evaluation pretreatment apparent diffusion coefficient ( ADC ) b1000 signal intensity ( SI ) GIST visualize WB-DWI predictor time progression , determine progression-free survival ( PFS ) 2 . Evaluation WB-DWI use change high b-value SI ADC early treatment ( 2weeks start therapy ; allow optimal window 10-14 day ) early predictor time progression patient benefit accord RECIST ( stable disease + partial response + complete response ) 3 . Evaluation WB-DWI treatment follow-up 3 month initiation treatment . Confirmation prior publish pilot study ( Dunet V et al , J Nucl Med 2010 ) 4 . Comparison WB-DWI conventional CT image response assessment</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>patient advance , metastatic gastrointestinal stromal tumor treat regorafenib placebo case know contraindication MRI ( eg . pacemaker ) , patient admit study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>advanced</keyword>
	<keyword>metastatic</keyword>
	<keyword>gastro-intestinal</keyword>
	<keyword>stromal</keyword>
	<keyword>GIST</keyword>
	<keyword>regorafenib</keyword>
</DOC>